HNHui Ning

Hui Ning

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hui Ning has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Gan Liu

    Hesheng Beiyin (Qing Dao) Co. Ltd, Qingdao, Shandong, China

    2 shared publications
  • Huiya Huang

    Beijing SyngenTech Co., LTD, Zhongguancun Life Science Park, Changping District, Beijing, 102206, China

    2 shared publications
  • Qiang Liu

    Beijing SyngenTech Co., LTD, Zhongguancun Life Science Park, Changping District, Beijing, 102206, China

    2 shared publications
  • Zhen Xie

    MOE Key Laboratory of Bioinformatics and Bioinformatics Division, Center for Synthetic and Systems Biology, Department of Automation, Beijing National Research Center for Information Science and Technology, Tsinghua University, Beijing, China.

    2 shared publications
  • Baolai Li

    Department of Obstetrics, Qingdao Municipal Hospital, Qingdao, Shandong 266071, P.R. China

    1 shared publication
  • Jiajia Mai

    Phase I Clinical Research Center, The First Hospital of Jilin University, Jilin, China

    1 shared publication

Latest Publications

  • The spatial and single-cell analysis reveals remodeled immune microenvironment induced by synthetic oncolytic adenovirus treatment

    by Gan Liu, Qifan Hu, Shuguang Peng, Hui Ning, Jiajia Mai, Xi Chen, Minzhen Tao, Qiang Liu, Huiya Huang, Yun Jiang, et al.


  • Open Access

    Rational design of microRNA-responsive switch for programmable translational control in mammalian cells

    by Hui Ning, Gan Liu, Lei Li, Qiang Liu, Huiya Huang, Zhen Xie

    Artificial RNA translation modulation usually relies on multiple components, such as RNA binding proteins (RBPs) or microRNAs (miRNAs) for off-switches and double-inverter cascades for on-switches. Recently, translational circular RNAs (circRNAs) were developed as promising alternatives for linear messenger RNAs (mRNAs). However, circRNAs still lack straightforward and programmable translation control strategies. Here, we rationally design a programmable miRNA-responsive internal ribosome entry site (IRES) translation activation and repression (PROMITAR) platform capable of implementing miRNA-based translation upregulation and downregulation in a single RNA construct. Based on the PROMITAR platform, we construct logic gates and cell-type classifier circRNAs and successfully identify desired mammalian cell types. We also demonstrate the potential therapeutic application of our platform for targeted cancer cell killing by encoding a cytotoxic protein in our engineered circRNAs. We expect our platform to expand the toolbox for RNA synthetic biology and provide an approach for potential biomedical applications in the future.


  • Open Access

    Expression and role of microRNA 18b and hypoxia inducible factor‑1α in placental tissues of preeclampsia patients

    by Shenglan Wang, Xuemei Wang, Zhanping Weng, Shuping Zhang, Hui Ning, Baolai Li

    Abnormal expression of hypoxia inducible factor‑1α (HIF‑1α) is closely associated with various diseases. By detecting the mRNA and protein expression levels of microRNA 18b (miR‑18b) and HIF‑1α in placental tissues of preeclampsia (PE) patients and studying the effects of miR‑18b on total cellular metabolic activity, migration and invasion in normal human trophoblast cell lines (HTR‑8/SVneo), the present study aimed to investigate the effect of miR‑18b on targeted regulation of HIF‑1α and its clinical significance in the development of PE. Expression levels of miR‑18b and HIF‑1α mRNA in PE placental tissues were detected by reverse transcription‑quantitative polymerase chain reaction and corresponding expression levels of HIF‑1α protein were analyzed by western blotting. miR‑18b overexpression and inhibited miR‑18b expression in HTR‑8/SVneo cells, which were constructed by transfecting miR‑18b mimic and inhibitor, respectively, were investigated and the total cellular metabolic activity, migration and invasion abilities in different groups of cells were compared. Expression levels of miR‑18b were significantly reduced in PE placental tissues and miR‑18b inhibitor‑transfected HTR‑8/SVneo cells, whereas the expression levels of HIF‑1α were significantly increased in PE placental tissues and significantly decreased in miR‑18b mimic‑transfected HTR‑8/SVneo cells. Overexpression of miR‑18b inhibited the expression of HIF‑1α and reduced the cell invasion, migration and viability of HTR‑8/SVneo cells. However, inhibition of miR‑18b expression promoted the expression of HIF‑1α and increased the cell invasion, migration and total cellular metabolic activity of HTR‑8/SVneo cells. The present study indicated that abnormal expression of HIF‑1α exhibited in PE placental tissues was regulated by miR‑18b. Furthermore miR‑18b expression was demonstrated to affect cell invasion, migration and viability through target regulation of HIF‑1α. The results of the present study suggest that miR‑18b and HIF‑1α may have important roles in the development of PE.


  • Application of iPS in Assisted Reproductive Technology: Sperm from Somatic Cells?

    by Lin Yao, Xiya Yu, Ning Hui, Shanrong Liu

    Infertility is an emotionally charged problem, and it is a condition of increasing incidence. In addition, in 40% to 60% of all infertile couples, it was the male who had a problem that led to infertility. Among the male fertility problems, non-obstructive azoospermia (NOA) (caused by testis failure or impaired spermatogenesis) is the most prevalent. Despite enormous clinical and experimental efforts, treatment of this disorder—assistant reproduction technique (ART) with donor spermatozoa remains controversial. We present the hypothesis that induced pluripotent stem (iPS) cell derived spermatozoa can be a potential source for male gametes for patients with NOA; we support this with the following three evidence: the first is the generation of viable, live-born, fertile mature organism from iPS cells; the second is the successful induced differentiation of male gametes from pluripotent cells in vitro; and the last is the wide use of intracytoplasmic sperm injection (ICSI) in human assisted reproduction. If the hiPS derived spermatozoa prove practical in the generation offspring with ICSI, this method might be able to grant a new chance for NOA patients to have their genetic children with fewer emotional, ethical and legislative problems. To ensure the safety of the technology itself and the production of healthy offspring, further investigations are needed. We also suggest several laboratory and clinical approaches for testing our hypothesis.